1260023-79-7

Usage

Uses

Used in Organic Synthesis:
3-Chloro-4-isopropoxyphenylboronic acid pinacol ester is used as a building block in organic synthesis for the preparation of pharmaceuticals and agrochemicals. Its unique structure and reactivity allow for the creation of a wide range of complex organic molecules with potential applications in various industries.
Used in Suzuki-Miyaura Cross-Coupling Reactions:
In the field of organic chemistry, 3-Chloro-4-isopropoxyphenylboronic acid pinacol ester is utilized as a key component in Suzuki-Miyaura cross-coupling reactions. These reactions are essential for the formation of carbon-carbon bonds, which are crucial in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
3-Chloro-4-isopropoxyphenylboronic acid pinacol ester is used as an intermediate in the synthesis of various pharmaceutical compounds. Its high reactivity and stability make it an ideal candidate for the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Chloro-4-isopropoxyphenylboronic acid pinacol ester is employed as a precursor for the synthesis of various agrochemicals, such as pesticides and herbicides. Its use in this industry contributes to the development of more effective and environmentally friendly solutions for crop protection and management.

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 201849-21-0 4-bromo-2-chloro-1-[(1-methylethyl)oxy]benzene 
• 3964-56-5 4-bromo-2-chlorophenol 

Downstream Products

• 1258440-38-8 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazole 
• 1334608-06-8 2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-[2-ethyl-3-(4-piperidinyl)phenyl]pyrimidine 
• 1334608-07-9 ethyl 3-{4-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]-1-piperidinyl}propanoate 
• 1334608-08-0 ethyl 4-{4-[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]-1-piperidinyl}butanoate 
• 1334608-21-7 ethyl 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoate 
• 1334607-75-8 4-{[3-(2-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-5-pyrimidinyl)-2-ethylphenyl]oxy}butanoic acid 
• 1426319-67-6 6-[3-chloro-4-(propan-2-yloxy)phenyl]pyrimidine-4-carboxylic acid 
• 1344996-09-3 1-(3-(5-(3-chloro-4-isopropoxyphenyl)-1,2,4-thiadiazol-3-yl)-2-ethylphenethyl)azetidine-3-carboxylic acid 
• 1344996-11-7 1-(3-(5-(3-chloro-4-isopropoxyphenyl)-1,2,4-thiadiazol-3-yl)-2-ethylphenethyl)piperidine-4-carboxylic acid 
• 1344996-12-8 1-(3-(5-(3-chloro-4-isopropoxyphenyl)-1,2,4-thiadiazol-3-yl)-2-ethylbenzyl)azetidine-3-carboxylic acid 
• 1373522-30-5 4-(5-(5-(3-chloro-4-isopropoxyphenyl)-1,2,4-thiadiazol-3-yl)-4-ethylpyridin-3-yl)butanoic acid 
• 1260023-67-3 2-(3-(5-(3-chloro-4-isopropoxyphenyl)-1,2,4-thiadiazol-3-yl)-2-ethylphenyl)acetaldehyde 
• 1373522-41-8 5-(3-chloro-4-isopropoxyphenyl)-3-(2-ethyl-3-(2-methoxyvinyl)phenyl)-1,2,4-thiadiazole 
• 1344997-59-6 3-(5-(3-chloro-4-isopropoxyphenyl)-1,2,4-thiadiazol-3-yl)-2-ethylbenzaldehyde 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

METHODS AND COMPOSITIONS FOR TREATING HIV-RELATED DISORDERS

Certain adjunctive therapies comprising a kynurenine-3-monooxygenase inhibitor and an antiviral agent for treating HIV-related disorders are provided herein. These disorders include AIDS dementia complex, AIDS-induced encephalopathy, HIV-associated neurocognitive disorder, asymptomatic neurocognitive impairment, minor neurocognitive disorder, minor cognitive motor disorder, vacuolar myelopathy, peripheral neuropathies, and polymyositis. Also provided are pharmaceutical compositions comprising a kynurenine-3- monooxygenase inhibitor and an antiviral agent.

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as a sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as sphingosine 1- phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS

Compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by S1P1 receptors.

5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS

5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.